Enlicitide chloride is a potent PCSK9 antagonist. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, percholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders[1].
References:
[1]. Ding FX, et al. Preparation of cyclic peptides as PCSK9 antagonist compounds: World Intellectual Property Organization, WO2019246349. 2019-12-26. [2]. WHO Drug Information-World Health Organization (WHO).